secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acurx Pharmaceuticals, Inc. (ACXP)
CIK:        0001736243
Form:       8-K
Filed at:   2023-05-17T23:59:59+00:00
Accession:  0001104659-23-061848
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 3.02, 3.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acurx Pharma prices $4M registered direct offering of common stock and warrants
-------------------------------------------------------------------------------

- Gross proceeds of ~$4M from sale of 1,333,333 shares (or pre-funded warrants) at $3.00 per share.
- Concurrent private placement of Series C and D warrants to purchase up to 2,666,666 shares at $3.26, exercisable after 6 months.
- Existing Series A and B warrants amended to extend expiry to May 18, 2029.
- Offering expected to close May 18, 2023; Maxim Group LLC as placement agent.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736243/000110465923061848/0001104659-23-061848-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736243/000110465923061848/tm2315976d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-061848

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer